Bio-Rad Laboratories, Inc. (NYSE:BIO) has launched a line of antibodies specific to cemiplimab (Libtayo).
The antibodies inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1).
Hercules, California–based Bio-Rad Lab, said the ready-made antibodies could be used to develop selective and sensitive assays for bioanalysis and drug monitoring of cemiplimab.
Cemiplimab, developed by Regeneron and Sanofi-Aventis U.S., acts as a checkpoint inhibitor by binding to PD-1 on T cells.
It blocks the interaction with its ligands, PD-L1 and PD-L2, to activate T cells to attack cancer cells.
Bio-Rad reports that the anti-cemiplimab antibodies with varying degrees of affinity provide flexibility for bioanalytical ligand binding assays.
“These critical antibody reagents support researchers developing bioanalytical assays for checkpoint inhibitor drugs by providing sequence-defined, well-characterized reagents with stable supply,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group, in a press release. “The introduction of TrailBlazer Antibodies to the range brings added flexibility for bioanalytical assay design,” she said.